It is now estimated that nearly 1 in 10 people who have a SARS-CoV-2 infection (hospitalized and non-hospitalized individuals) may develop Long COVID, which amounts to a global burden of over 16 million people.
A CITF-funded study, published in the International Journal of Infectious Diseases, explored whether COVID-19 vaccination in people with post-COVID-19 condition (PCC), also known as Long COVID, could affect their symptoms, immune responses, and viral persistence.
A CITF-funded study, published in preprint and not yet peer-reviewed, provided valuable insights into the mechanisms of myocardial inflammation and its effects on heart function using a heart-on-a-chip model.
A CITF-funded study, published in preprint and not yet peer-reviewed, found positive associations between Post COVID-19 Condition (PCC), also known as Long COVID, and anti-spike (S), and anti-receptor binding domain (RBD) IgG titres, which were not statistically significant.
A study funded by the CITF and the Canadian Institutes of Health Research and led by Dr. Manali Mukherjee (McMaster University) has found two things: that in most people with persistent COVID symptoms, long COVID does not last forever and a possible link between long COVID and autoimmune disease.